AlphaMark Advisors’s Amicus Therapeutics FOLD Stock Holding History

AlphaMark Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-146	Closed	-$1K	–	465
2016 Q3	$1K	Hold	146	–	–	﹤0.01%	332
2016 Q2	$1K	Hold	146	–	–	﹤0.01%	322
2016 Q1	$1K	Hold	146	–	–	﹤0.01%	305
2015 Q4	$1K	Hold	146	–	–	﹤0.01%	295
2015 Q3	$2K	Hold	146	–	–	﹤0.01%	271
2015 Q2	$2K	Hold	146	–	–	﹤0.01%	280
2015 Q1	$2K	Hold	146	–	–	﹤0.01%	284
2014 Q4	$1K	Hold	146	–	–	﹤0.01%	285
2014 Q3	$1K	Buy	+146	New	+$765	﹤0.01%	308

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

AlphaMark Advisors's FOLD Position: Q4 2016 in Review

AlphaMark Advisors sold out of Amicus Therapeutics (FOLD) in Q4 2016, closing a stake of 146 shares — an estimated $1K sold.

AlphaMark Advisors first reported a position in FOLD in Q3 2014 and held it in 9 quarters. The position peaked at $2K in Q3 2015. 135 funds tracked by Wall St. Rank hold FOLD as of Q4 2016.

AlphaMark Advisors reported no remaining Amicus Therapeutics position as of Q4 2016 after selling out during the quarter.
AlphaMark Advisors sold 146 Amicus Therapeutics shares in Q4 2016, an estimated $1K.
AlphaMark Advisors first reported a position in Amicus Therapeutics in Q3 2014 and held it in 9 quarters.
AlphaMark Advisors's Amicus Therapeutics position peaked at $2K in Q3 2015.
135 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2016.

Based on AlphaMark Advisors's 13F filing for Q4 2016, filed 26 Jan 2017.